Edgewise closes muscular-dystrophy biz sale in deal that could top $2.6M
Boulder drug maker will now focus on cardiovascular diseases
Edgewise recently closed on a deal to sell its muscular-dystrophy business to French pharmaceutical company Les Laboratoires Servier.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
The Community Builder Awards is a program created to salute Boulder Valley and Northern Colorado’s…
-
Edgewise Therapeutics has clarified its relationship with a clinical researcher who recently received a warning…
-
Edgewise Therapeutics Inc., (Nasdaq: EWTX), a Boulder-based muscle-disease biopharmaceutical company, maintained a strong cash balance…
-
Edgewise Therapeutics plans to sell nearly 10 million shares of its common stock at $20.13,…
